Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 5,198 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Neoplasm Clear all
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors

NCT00632281
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 22, 2026, 4:18 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567
View directory record Official record
Conditions
Small-Cell Lung Cancer
Interventions
Atezolizumab, Lurbinectedin, Carboplatin, Etoposide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Marietta, Georgia • Peoria, Illinois • Scarborough, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 4:18 PM EDT
Not listed No phase listed Observational

Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath Lung Assay

NCT05870592
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
bioAffinity Technologies Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 22, 2026, 4:18 PM EDT
Terminated Phase 3 Interventional

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

NCT00738387
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ASA404, Placebo, docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
88
States / cities
Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

NCT00046787
View directory record Official record
Conditions
SCLC, Carcinoma, Small Cell
Interventions
OSI-211 (Liposomal Lurtotecan)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Tucson, Arizona • Denver, Colorado • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Oct 22, 2026, 4:18 PM EDT
Active, not recruiting Phase 1 Interventional

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339
View directory record Official record
Conditions
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions
NBTXR3, SABR, Nivolumab, Pembrolizumab
Drug · Radiation
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Results available

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

NCT01090011
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab, BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Aurora, Colorado • New Haven, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 22, 2026, 4:18 PM EDT
Terminated Phase 2 Interventional

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions
Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg
Drug · Biological · Dietary Supplement
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 22, 2026, 4:18 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

NCT03745222
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Los Angeles, California • Jacksonville, Florida • Winter Haven, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 22, 2026, 4:18 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
51
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

NCT00653939
View directory record Official record
Conditions
Tumors
Interventions
Fosbretabulin, Carboplatin, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00006012
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions
filgrastim, amifostine trihydrate, cisplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
84
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 22, 2026, 4:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

NCT04106492
View directory record Official record
Conditions
Cancer
Interventions
SQ3370
Drug
Lead sponsor
Shasqi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Duarte, California • Palo Alto, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 1 Interventional

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

NCT01460134
View directory record Official record
Conditions
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
Interventions
CDX-1127
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

NCT01027598
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pazopanib, Erlotinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Fort Myers, Florida • Lawrenceville, Georgia • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 22, 2026, 4:18 PM EDT
Recruiting Not applicable Interventional

A Study of Hospital-at-Home for People Receiving Tarlatamab

NCT06957314
View directory record Official record
Conditions
Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
Hospital-at-Home/HAH
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 4:18 PM EDT
Terminated Not applicable Interventional Results available

Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)

NCT00881712
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PET positive nodal disease measuring 15 mm or greater, PET positive nodal disease measuring less than 15 mm, Patients considered resectable
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT02013219
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib, Atezolizumab, Erlotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
Orange, California • New Haven, Connecticut • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Not applicable Interventional

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00823732
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 22, 2026, 4:18 PM EDT
Completed No phase listed Observational Results available

A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer

NCT02239328
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00245063
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer
Interventions
cediranib maleate, laboratory biomarker analysis, pharmacogenomic studies
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 22, 2026, 4:18 PM EDT
Completed Phase 2 Interventional

Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT00865319
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), 18 F fluorodeoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Coral Gables, Florida • Decatur, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 22, 2026, 4:18 PM EDT
Withdrawn Phase 2 Interventional

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NCT03628144
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage ⅢA, NSCLC Stage IIIB, NSCLC, Stage IIIA
Interventions
Impact® Advanced Recovery, Boost® High Protein, Radiation Therapy, Chemotherapy, Quality of life (EORTC-QLQ-30), Evaluation of Cognitive Function (FACT-Cog, v. 3.0), Mindfulness Questionnaire (FFMQ)
Dietary Supplement · Radiation · Drug + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 22, 2026, 4:18 PM EDT
Completed No phase listed Observational

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

NCT03137264
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Other
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • Santa Rosa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 22, 2026, 4:18 PM EDT